Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Operating Cash Flow
Cash generated by the company's core business operations during the period.
Solid Biosciences Inc.NASDAQ: SLDB
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $47.23M (cash outflow) rose 48.3% year over year, behind the +60.9% change in trailing-twelve-month operating cash flow. Sequentially, it fell 11.8% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +48.3% toward the trailing-twelve-month pace of +60.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (156.29M) USD
- Year-over-year change
- -56.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (156.29M) | -56.3% |
| FY2024 | 2024-12-31 | (100.01M) | -6.2% |
| FY2023 | 2023-12-31 | (94.18M) | +3.9% |
| FY2022 | 2022-12-31 | (97.98M) | -26.0% |
| FY2021 | 2021-12-31 | (77.76M) | — |
Operating Cash Flow vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 operating cash flow of $171.67M is the 4th largest of the 10 companies compared; the peer median is $81.94M.
- Its year-over-year change of +60.9% is the 4th highest of 10, against a peer median of +32.9%.
- Over three fiscal years its annual growth of +16.8% compares with a peer median of +11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $477.82M | +32.9% | +37.9% | — | |
| LTM Sep 2026 | $201.9M | +52.7% | +39.8% | — | |
| LTM Mar 2026 | $175.28M | +132.0% | -14.2% | 8.0% | |
| LTM Mar 2026 | $171.67M | +60.9% | +16.8% | — | |
| LTM Mar 2026 | $129.45M | -15.5% | +8.0% | 146.7% | |
| LTM Mar 2026 | $92.63M | +105.1% | — | — | |
| LTM Mar 2026 | $81.94M | +17.5% | +13.5% | — | |
| LTM Mar 2026 | $77.13M | -6.8% | +11.3% | — | |
| LTM Jun 2026 | $30.5M | -104.3% | — | 3.0% | |
| LTM Mar 2026 | $8.28M | +107.9% | -14.1% | 10.4% | |
| Peer median (excluding SLDB) | $81.94M | +32.9% | +11.3% | 9.2% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | (1.87M) |
| Deferred Income Tax | 1.21M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M |
| Change in Working Capital | (23.04M) | (3.69M) | (6.34M) | 2.85M | (6.82M) |
| Accounts Receivables | (110K) | 110K | 0 | 0 | 0 |
| Inventory | (11.5M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.21M | (5.25M) | (764K) | 2.21M | (1.09M) |
| Other Working Capital | (12.64M) | 1.45M | (5.57M) | 645K | (5.73M) |
| Other Non-Cash Items | (81K) | (18.25M) | (2.03M) | 8.86M | 9.82M |
| Operating Cash Flow | (77.76M) | (97.98M) | (94.18M) | (100.01M) | (156.29M) |
| Capital Expenditures | (1.28M) | (3.02M) | (1.52M) | (654K) | (1.15M) |
| Acquisitions (Net) | 89.81M | 31.52M | 0 | 5K | 85K |
| Purchases of Investments | (141.25M) | (182.76M) | (117.43M) | (204.34M) | (235.89M) |
| Sales of Investments | 51.44M | 212.81M | 128.63M | 188.9M | 178.5M |
| Other Investing Activities | (89.81M) | 600K | 0 | 0 | 0 |
| Investing Cash Flow | (91.09M) | 59.16M | 9.69M | (16.09M) | (58.45M) |
| Debt Repayment | 0 | 2.08M | 0 | (473K) | (723K) |
| Common Stock Issued | 134.88M | 72.55M | 2.97M | 127.23M | 194.74M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.11M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 107K | 203K | 148K | 794K | 425K |
| Financing Cash Flow | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (33.87M) | 36.01M | (81.37M) | 6.34M | (20.3M) |
| Free Cash Flow | (79.05M) | (100.99M) | (95.7M) | (100.67M) | (157.44M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.